Multiple myeloma (management of newly diagnosed patients): literature review and our on data. Part II

S.S. Bessmeltsev,

DOI:

https://doi.org/10.21320/2500-2139-2013-6-4-379-414

Over the last decades, survival rates for young patients with multiple myeloma markedly increased mainly due to the use of autologous stem cell transplantation (ASCT) and new highly efficacious rescue therapies. In patients with multiple myeloma over 65 years of age, a combination of melphalan and prednisone (MP) is traditionally used. Introduction of novel agents such as immunomodulatory drugs (IMiDs) and proteasome inhibitors substantially changed the therapeutic approach to the disease. Many double-, triple-, and quadruple-agent combinations were studied in the patients with newly diagnosed multiple myeloma. It was established that the achievement of complete response (CR) is an independent predictor of prolonged progression-free survival (PFS) and overall survival (OS). The data from prospective trials completed suggest that the best available strategy to achieve high CR rates and prolong its duration includes an induction therapy with a triple-agent bortezomib- or IMiDs-based regimen followed by ASCT and consolidation/maintenance with IMiDs or proteasome inhibitors. The vast majority of elderly patients with MM are ineligible for ASCT. Introduction of novel agents such as thalidomide, bortezomib, or lenalidomide considerably improved the treatment outcomes. MPT (MP + thalidomide), VMP (MP + bortezomib), and MPR-R (MP + lenalidomide) regimens are currently regarded as the new standards of care for elderly patients with multiple myeloma. The prognosis for multiple myeloma is determined by numerous factors, all of which should be considered when choosing the initial therapy. This review covers the new strategies based on the current studies being conducted that are aimed at optimizing treatment outcomes in the patients with newly diagnosed multiple myeloma.

  • S.S. Bessmeltsev Russian Research Institute of Hematology and Transfusiology, FMBA, Saint Petersburg, Russian Federation ; ФГБУ «Российский научно-исследовательский институт гематологии и трансфузиологии Федерального медико-биологического агентства», Санкт-Петербург, Российская Федерация
  1. Бессмельцев С.С., Абдулкадыров К.М. Множественная миелома. Со- временный взгляд на проблему. Алматы: Коста, 2007. [Bessmeltsev S.S., Abdulkadyrov K.M. Mnozhestvennaya miyeloma. Sovremennyy vzglyad na problemu (Multiple myeloma. Current view of the problem). Almaty: Kosta, 2007.]
  2. Kumar S.K., Rajkumar S.V., Dispenzieri A. et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008; 111(5): 2516–20. DOI: https://doi.org/10.1182/blood-2007-10-116129
  3. San-Miguel J.F., Mateos M.-V. How to treat a newly diagnosed young patient with multiple myeloma. Hematology (American Society of Hematology Education Program Book, New Orleans, Louisiana, December 508, 2009) 2009: 555–65. DOI: https://doi.org/10.1182/asheducation-2009.1.555
  4. Rajkumar S. V., Harousseau J.-L., Durie B. et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International myeloma workshop consensus panel 1. Blood, prepublished online Feb 3, 2011; doi:10.1182/blood-2010-10-299487. DOI: https://doi.org/10.1182/blood-2010-10-299487
  5. Dimopoulos M., Kyle R., Fermand J.-P. et al. Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. Blood 2011; 117(18): 4701–5. DOI: https://doi.org/10.1182/blood-2010-10-299529
  6. Landgren O., Katzmann J.A., Hsing A.W. et al. Prevalence of monoclonal gammopathy of undetermined significance among men in Ghana. Mayo Clin. Proc. 2007; 82(12): 1468–73. DOI: https://doi.org/10.1016/S0025-6196(11)61089-6
  7. Iwanaga M., Tagawa M., Tsukasaki K. et al. Prevalence of monoclonal gammopathy of undetermined significance: study of 52,802 persons in Nagasaki City, Japan. Mayo Clin. Proc. 2007; 82(12): 1474–9. DOI: https://doi.org/10.1016/S0025-6196(11)61090-2
  8. Kyle R.A., Remstein E.D., Therneau T.M. et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. New Engl. J. Med. 2007; 356(25): 2582–90. DOI: https://doi.org/10.1056/NEJMoa070389
  9. Kumar S. K., Mikhael J.R., Buadi F.K. et al. Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines. Mayo Clin. Proc. 2009; 84(12): 1095–110. DOI: https://doi.org/10.4065/mcp.2009.0603
  10. Euler H.H., Schmitz N., Loffler H. Plasmapheresis in Paraproteinemia. Blut 1985; 50(6): 321–30. DOI: https://doi.org/10.1007/BF00320925
  11. Attal M., Huguet F., Schlaifer D. et al. Intensive combined therapy for previously untreated aggressive myeloma. Blood 1992; 79: 1130–6. DOI: https://doi.org/10.1182/blood.V79.5.1130.bloodjournal7951130
  12. Alexanian R., Dimopoulos M.A., Hester I. et al. Early myeloablative therapy for multiple myeloma. Blood 1994; 84(12): 4278–82. DOI: https://doi.org/10.1182/blood.V84.12.4278.bloodjournal84124278
  13. Abdulkadyrov K.M., Bessmeltsev S.S. Use of VCAP, ARA-COP and VAD schedules in treatment of patients with multiple myeloma. Abstracts of the XVI International Cancer Congress. New Delhi (India), 1995. Abstract NA-02807.
  14. Bergsagel D.E., Pruzanski P.W. Some unusual manifestations of plasma cell neoplasma. In: Neoplastic disease of the Blood. Ed. by P.H. Wiernik. New York, 1985: 553–73.
  15. Абдулкадыров К.М., Бессмельцев С.С. Сравнительная оценка эффективности программ моно- и полихимиотерапии больных множественной миеломой. Клин. мед. 1992; 9(10): 57–60. [Abdulkadyrov K.M., Bessmeltsev S.S. Sravnitelnaya otsenka effektivnosti programm mono- i polikhimioterapii bolnykh mnozhestvennoy miyelomoy (Comparative evaluation of efficacy of mono- and polychemotherapy programs in patients with multiple myeloma. In: Clin. med.). Klin. med. 1992; 9(10): 57–60.]
  16. Birgens H.S., Hansen O.P., Clausen N.T. et al. A methodological evaluation of 14 controlled clinical trials in myelomatosis. Scand. J. Haematol. 1985; 35: 26–34. DOI: https://doi.org/10.1111/j.1600-0609.1985.tb00795.x
  17. Merlini G., Riccardi A., Riccardi R.G. et al. Peptichemio, vincristine, prednisone induction treatment in multiple myeloma. Tumors 1985; 71: 581–8. DOI: https://doi.org/10.1177/030089168507100611
  18. Бессмельцев С.С., Стельмашенко Л.В. Сравнительная оценка различных методов лечения больных с множественной миеломой. Эфферентная тер. 2000; 2: 54–63. [Bessmeltsev S.S., Stelmashenko L.V. Sravnitelnaya otsenka razlichnykh metodov lecheniya bolnykh s mnozhestvennoy miyelomoy (Comparative evaluation of various therapeutic methods in patients with multiple myeloma. In: Efferent ther.). Efferentnaya ter. 2000; 2: 54–63.]
  19. Palva I.P., Ahrenberg P., Ala-Harja K. et al. Treatment of multiple myeloma in old patients. Eur. J. Haematol. 1989; 43: 328–31. DOI: https://doi.org/10.1111/j.1600-0609.1989.tb00307.x
  20. Hernandez J.M., Garcia-Sanz R., Golvano E. et al. Randomized comparison of dexamethasone combined with melphalan versus melphalan with prednisone in the treatment of elderly patients with multiple myeloma. Br. J. Haematol. 2004; 127(2): 159–64. DOI: https://doi.org/10.1111/j.1365-2141.2004.05186.x
  21. Facon T., Mary J.Y., Pegourie B. et al. Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy. Blood 2006; 107: 1292–8. DOI: https://doi.org/10.1182/blood-2005-04-1588
  22. Riccardi A., Ucci G., Luoni R. et al. Treatment of multiple myeloma according to the extension of the disease: a prospective, randomized study comparing a less with a more aggressive cytostatic policy. Cooperative Group of Study and Treatment of Multiple myeloma. Br. J. Cancer 1994; 70: 1203–10. DOI: https://doi.org/10.1038/bjc.1994.474
  23. Бессмельцев С.С. Современные подходы к химиотерапии множе- ственной миеломы. Медико-фармацевтический форум (29 октября — 2 но- ября): Тезисы докладов. М., 2002: 36–7. [Bessmeltsev S.S. Sovremennyye podkhody k khimioterapii mnozhestvennoy miyelomy. Mediko-farmatsevticheskiy forum (29 oktyabrya — 2 noyabrya): Tezisy dokladov (Current approaches to chemotherapy for multiple myeloma. Medico-pharmaceutical forum (October 29–November 2): talking points in presentations). M., 2002: 36–7.]
  24. Oken M.M., Kyle R.A., Greipp P.R. et al. Complete remission induction with combined VBMCP chemotherapy and interferon in patients with multiple myeloma. Leuk. Lymphoma 1996; 20: 447–52. DOI: https://doi.org/10.3109/10428199609052427
  25. Oken M.M., Harrington D.P., Abramson N. et al. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479. Cancer 1997; 79: 1561–7. DOI: https://doi.org/10.1002/(SICI)1097-0142(19970415)79:8<1561::AID-CNCR18>3.0.CO;2-W
  26. Finnish Leukemia Group. Treatment of multiple myeloma in old patients. Eur. J Haematol. 1989; 43: 328–31.
  27. Kumar S., Lacy M.Q., Dispenzieri A. et al. Single agent dexamethasone for pre-stem cell transplant induction therapy for multiple myeloma. Bone Marrow Transplant. 2004, advance online publication 2 August 2004; doi:10.1038/ sj.bmt. 1704633.
  28. Cook G., Clark R.E., Morris T.C. A randomized study (WOS MM1) comparing the oral regime Z-Dex (idarubicin and dexamethasone) with vincristine, adriamycin and dexamethasone as induction therapy for newly diagnosed patients with multiple myeloma. Br. J. Haematol. 2004; 126: 792–8. DOI: https://doi.org/10.1111/j.1365-2141.2004.05127.x
  29. Munshi N.C., Anderson K.C., Bergsagel P.L. et al. Guidelines for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood, Prepublished online Feb 3, 2011; doi:10.1182/ blood-2010-10-300970.
  30. Kyle R.A., Rajkumar S.V. Multiple myeloma. N. Engl. J. Med. 2004; 351: 1060–77. DOI: https://doi.org/10.1056/NEJMra041875
  31. Barlogie B., Shaughnessy J., Tricot G. et al. Treatment of multiple myeloma. Blood 2004; 103: 20–32. DOI: https://doi.org/10.1182/blood-2003-04-1045
  32. Palumbo A., Gay F. How to treat elderly patients with multiple myeloma: combination of therapy or sequencing. Hematology 2009 (American Society of Hematology Eduction Program Book, New Orleans, Louisiana, December 508, 2009): 566–77. DOI: https://doi.org/10.1182/asheducation-2009.1.566
  33. Blade J., Samson D., Reece D. et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br. J. Haematol. 1998; 102(5): 1115–23. DOI: https://doi.org/10.1046/j.1365-2141.1998.00930.x
  34. Durie B.G.M., Harousseau J.-L., San-Miguel J. et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20(9): 1467–73. DOI: https://doi.org/10.1038/sj.leu.2404284
  35. Paiva B., Vidriales M.B., Cervero J. et al. Multiparameter flow cytometry remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood 2008; 112: 4017–23. DOI: https://doi.org/10.1182/blood-2008-05-159624
  36. Corradini P., Cavo M., Lokhorst H. et al. Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma. Blood 2003; 102: 1927–9. DOI: https://doi.org/10.1182/blood-2003-01-0189
  37. Brenner H., Gondos A., Pulte D. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood 2008; 111(5): 2521–6. DOI: https://doi.org/10.1182/blood-2007-08-104984
  38. D’Amato R.J., Loughnan M.S., Flynn E. et al. Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. Sci. U S A 1994; 91: 4082–5. DOI: https://doi.org/10.1073/pnas.91.9.4082
  39. Mitsiades N., Mitsiades C.S., Poulaki V. et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 2002; 99(12): 4525–30. DOI: https://doi.org/10.1182/blood.V99.12.4525
  40. Kyle R.A., Rajkumar S.V. Therapeutic application of thalidomide in multiple myeloma. Semin. Oncol. 2001; 28: 583–7. DOI: https://doi.org/10.1053/sonc.2001.28612
  41. Rajkumar S.V., Blood E., Vesole D. et al. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J. Clin. Oncol. 2006; 24: 431–6. DOI: https://doi.org/10.1200/JCO.2005.03.0221
  42. Rajkumar S.V., Rosinol L., Hussein M. et al. Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. J. Clin. Oncol. 2008; 26: 2171–7. DOI: https://doi.org/10.1200/JCO.2007.14.1853
  43. Cavo M., Zamagni E., Tosi P. et al. Superiority of thalidomide and dexamethasone over vincristine-doxorubicin-dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 2005; 106: 35–9. DOI: https://doi.org/10.1182/blood-2005-02-0522
  44. Lokhorst H.M., Schmidt-Wolf I., Sonneveld P. et al. Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma. Haematologica 2008; 93: 124–7. DOI: https://doi.org/10.3324/haematol.11644
  45. Zervas K., Mihou D., Katodritou E. et al. VAD-doxil versus VAD-doxil plus thalidomide as initial treatment for multiple myeloma: results of a multicenter randomized trial of the Greek myeloma study group. Ann. Oncol. 2007; 18: 1369–75. DOI: https://doi.org/10.1093/annonc/mdm178
  46. Marco M., Divine M., Uzunhan Y. et al. Dexamethasone+thalidomide (Dex/Thal) compared to VAD as a pre-transplant treatment in newly diagnosed multiple myeloma: a randomized trial. Blood 2006; 108: 57a (abstr.). DOI: https://doi.org/10.1182/blood.V108.11.57.57
  47. Morgan G.J., Faith D., Roger O. et al. Thalidomide combinations improve response rates; results from the MRC IX study. Blood 2007; 110: 3593 (abstr.). DOI: https://doi.org/10.1182/blood.V110.11.3593.3593
  48. Schafer P.H., Gandhi A.K., Loveland M.A. et al. Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs. J. Pharmacol. Exp. Ther. 2003; 305(3): 1222–32. DOI: https://doi.org/10.1124/jpet.102.048496
  49. Breitkreutz I., Raab M.S., Vallet S. et al. Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma. Leukemia 2008; 22(10): 1925–32. DOI: https://doi.org/10.1038/leu.2008.174
  50. Rajkumar S.V., Hayman S.R., Lacy M.Q. et al. Combination therapy with lenalidomide plus dexamethasone for newly diagnosed myeloma. Blood 2005; 106: 4050–3. DOI: https://doi.org/10.1182/blood-2005-07-2817
  51. Lacy M.Q., Gertz M.A., Dispenzieri A. et al. Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma. Mayo Clin. Proc. 2007; 82(10): 1179–84. DOI: https://doi.org/10.4065/82.10.1179
  52. Kumar S., Dispenzieri A., Lacy M.Q. et al. Impact of lenalidomide therapy on stem cell mobilization and engraftment postperipheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia 2007; 21: 2035–42. DOI: https://doi.org/10.1038/sj.leu.2404801
  53. Kumar S., Giralt S., Stadtmauer E.A. et al. Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens. Blood 2009; 114: 1724–35. DOI: https://doi.org/10.1182/blood-2009-04-205013
  54. Zonder J.A., Crowley J., Hussein M.A. et al. Lenalidomide and highdose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232). Published online before print September 27, 2010, doi:10.1182/blood-2010- 08-303487. DOI: https://doi.org/10.1182/blood-2010-08-303487
  55. Rajkumar S.V., Jacobus S., Callander N.S. et al. Randomized trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed myeloma, a trial coordinated by the Eastern Cooperative Oncology Group: analysis of response, survival, and outcome. J. Clin. Oncol. 2008; 26: 8504 (abstr.). DOI: https://doi.org/10.1200/jco.2008.26.15_suppl.8504
  56. Rajkumar S.V., Jacobus S., Callander N.S. et al. Lenalidomide plus highdose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma. An open-label randomised controlled trial. Lancet Oncol. 2010; 11: 29–37. 57. Kumar S.K., Lacy M.Q., Hayman S.R. et al. Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: Results from a phase 2 trial. Am. J. Hematol. 2011; 86(8): 640–5. DOI: https://doi.org/10.1016/S1470-2045(09)70284-0
  57. Niesvizky R., Jayabalan D.S., Christos P.J. et al. ViRD (Biaxian [clarithromycyn]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in highe complete- and overall-response rates in treatment-naive symptomatic multiple myeloma. Blood 2008; 111: 1101–9. DOI: https://doi.org/10.1182/blood-2007-05-090258
  58. Ohara T., Morishita T., Suzuki H. et al. Antibiotics directly induce apoptosis in B cell lymphoma cells derived from BALB/c mice. Anticancer Res. 2004; 24(6): 3723–30.
  59. Karin M., Cao Y., Greten F.R., Li Z.W. NF-kappaB in cancer: from innocent bystander to major culprit. Nat. Rev. Cancer 2002; 2: 301–10. DOI: https://doi.org/10.1038/nrc780
  60. Mitsiades N., Mitsiades C.S., Richardson P.G. et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2003; 101: 2377–80. DOI: https://doi.org/10.1182/blood-2002-06-1768
  61. Bessmeltsev S., Rugal V. Stromal microenvironment and stem cells niches in multiple myeloma. Hematologica (15th Congress of the European Hematology Association, Spain, Barcelona, June 10–13, 2010, Abstract Book): 569–70 (abstr. 1422).
  62. Hideshima T., Mitsiades C., Akiyama M. et al. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood 2003; 101: 1530–4. DOI: https://doi.org/10.1182/blood-2002-08-2543
  63. Terpos E., Heath D.J., Rahemtulla A. et al. Bortezomib reduced serum dick-kopf-1 and receptor activator of nuclear factor-kappaB ligand concentration and normalizes indices of bone remodelling in patients with relapsed multiple myeloma. Br. J. Haematol. 2006; 135: 688–92. DOI: https://doi.org/10.1111/j.1365-2141.2006.06356.x
  64. Von Metzler H., Krebbel M., Hecht R.A. et al. Bortezomib inhibits human osteoclastogenesis. Leukemia 2007; 21(9): 2025–34. DOI: https://doi.org/10.1038/sj.leu.2404806
  65. Zangari M., Terpos E., Zhan F., Tricot G. Impact of bortezomib on bone health in myeloma: A review of current evidence. Cancer Treatment Rev. 2012; 38: 968–80. DOI: https://doi.org/10.1016/j.ctrv.2011.12.007
  66. Jagannath S., Brian D., Wolf J.L. et al. A Phase 2 Study of Bortezomib as First-Line Therapy in Patients with Multiple Myeloma. Blood (ASH Annual Meeting Abstracts) 2004; 104: Abstract 333. DOI: https://doi.org/10.1182/blood.V104.11.333.333
  67. Harrousseau J., Mathiot C., Attal M. Bortezomib/dexamethasone versus VAD as induction prior to autologous stem cell transplantation in previously untreated multiple myeloma: Updated date from IFM 2005/01 trial (Abstract). J. Clin. Oncol. 2008; 26: 8505. DOI: https://doi.org/10.1200/jco.2008.26.15_suppl.8505
  68. Harrousseau J., Avet-Loiseau H., Attal M. et al. High complete and very good partial response rates with bortezomib-dexamethasone as induction prior to ASCT in newly diagnosed patients with high-risk myeloma: results of the IFM2005-01 phase 3 trial. ASH Annual Meeting Abstracts 2009; 114: 353. DOI: https://doi.org/10.1182/blood.V114.22.353.353
  69. Бессмельцев С.С., Стельмашенко Л.В., Карягина Е.В. и др. Новые подходы к лечению множественной миеломы. Вестн. Рос. воен.-мед. акад. 2010; 3: 149–54. [Bessmeltsev S.S., Stelmashenko L.V., Karyagina Ye.V. i dr. Novyye podkhody k lecheniyu mnozhestvennoy miyelomy (Novel approaches to treatment of multiple myeloma. In: Bull. of Rus. Mil. Med. Acad.). Vestn. Ros. voyen.-med. akad. 2010; 3: 149–54.]
  70. Jagannath S., Durie B., Wolf J. et al. First-line therapy with bortezomib (formerly PS-341) in patients with multiple myeloma. Proc. Am. Soc. Clin. Oncol. 2004; 23: 568 (abstr. 6551). DOI: https://doi.org/10.1200/jco.2004.22.90140.6551
  71. Oakervee H.E., Popat R., Curry N. et al. PAD combination therapy (PS- 341/bortezomib, doxorubicib and dexamethasone) for previously untreated patients with multiple myeloma. Br. J. Haematol. 2005; 129: 755–62. DOI: https://doi.org/10.1111/j.1365-2141.2005.05519.x
  72. Sonneveld P., van der Holt B., Schmidt-Wolf I.G.H. First analysis of HOVON-65/GMMG-HD4 randomized phase III trial comparing bortezomib, adriamycine, dexamethasone (PAD) vs VAD as induction treatment prior to high dose melphalan (HDM) in patients with newly diagnosed multiple myeloma. Blood 2008; 112: 653 (abstr.) DOI: https://doi.org/10.1182/blood.V112.11.653.653
  73. Бессмельцев С.С., Стельмашенко Л.В., Карягина Е.В. и др. Борте- зомиб в терапии 1-й линии при лечении множественной миеломы. Рос. мед. вести 2009; XIV(4): 29–37. [Bessmeltsev S.S., Stelmashenko L.V., Karyagina Ye.V. i dr. Bortezomib v terapii 1-y linii pri lechenii mnozhestvennoy miyelomy (Bortezomib in first-line therapy for multiple myeloma. In: Rus. med. news). Ros. med. vesti 2009; XIV(4): 29–37.]
  74. Бессмельцев С.С., Карягина Е.В., Стельмашенко Л.В. и др. Лечение молодых пациентов с впервые выявленной множественной миеломой. Украiн. журн. гематол. и трансфузiол. 2010; 5: 5–14. [Bessmeltsev S.S., Karyagina Ye.V., Stelmashenko L.V. i dr. Lecheniye molodykh patsiyentov s vpervyye vyyavlennoy mnozhestvennoy miyelomoy (Management of young patients with newly diagnosed multiple myeloma. In: Ukraine journ. of hematol. & transfusiol.) Ukrain. zhurn. gematol. i transfuziol. 2010; 5: 5–14.]
  75. Jakubowiak A.J., Friedman J., Kendall T. et al. A phase II study of combination of bortezomib, liposomal doxorubicin and dexamethasone (VDD) as first line therapy for multiple myeloma. J. Clin. Oncol. (ASCO Meeting Abstracts) 2006; 24: 18S (abstr. 17504). DOI: https://doi.org/10.1200/jco.2006.24.18_suppl.17504
  76. Moreau P., Pylypenko H., Grosicki S. et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomized, phase 3, non-inferiority study. Lancet 2011; 12(5): 431–40. DOI: https://doi.org/10.1016/S1470-2045(11)70081-X
  77. Alexanian R., Wang L.M., Weber D.M., Delasalle K.B. VTD (Velcade, Thalidomide, Dexamethasone) as Primary Therapy for Newly-Diagnosed Multiple Myeloma. Blood 2004; 104: Abstract 210. DOI: https://doi.org/10.1182/blood.V104.11.210.210
  78. Cavo M., Patriarca F., Tacchetti P. Superior complete response rate and progression-free survival after autologous transplantation with up-front velcadethalidomide-dexamethasone compared with thalidomide-dexamethasone in newly diagnosed multiple myeloma. Blood 2008; 112: 158 (abstr.). DOI: https://doi.org/10.1182/blood.V112.11.158.158
  79. Cavo M., Pantani L., Petrucci M.T. et al. Bortezomib-thalidomidedexamethasone is superior to thalidomide-dexamethasone as consolidation therapy following autologous hematopoietic stem-cell transplantation in patients with newly diagnosed multiple myeloma. Blood 2012; 120(1): 9–18. DOI: https://doi.org/10.1182/blood-2012-02-408898
  80. Rosinol L., Cibera M.T., Martinez J. Thalidomide/dexamethasone (TD) vs. bortesomib/thalidomide/dexamethasone (VTD) vs. VBMCP/VBAD/Velcade regimens prior autologous stem cell transplantation (ASCT) in younger patients with multiple myeloma: first results of a prospective phase III PETHEMA/Gem Trial. Blood 2008; 112: 654 (abstr.). DOI: https://doi.org/10.1182/blood.V112.11.654.654
  81. Richardson P.G., Weller E., Lonial S. et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 2010; 116(5): 679–86. DOI: https://doi.org/10.1182/blood-2010-02-268862
  82. Reeder C.B., Reece D.E., Kukreti V. et al. Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. Leukemia 2009; 23(7): 1337–41. DOI: https://doi.org/10.1038/leu.2009.26
  83. Kumar S., Flinn I.W., Noga S.J. et al. Safety and efficacy of novel combination therapy with bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in newly diagnosed multiple myeloma: initial results from the phase I/II multi-center EVOLUTION Study. Blood 2008; 112: 93 (abstr.). DOI: https://doi.org/10.1182/blood.V112.11.93.93
  84. Kumar S., Flinn I.W., Paul G. et al. Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood 2012; 119(19): 4375–82. DOI: https://doi.org/10.1182/blood-2011-11-395749
  85. Бессмельцев С.С., Карягина Е.В., Стельмашенко Л.В. и др. Эффек- тивность леналидомида при рефрактерных/рецидивирующих формах множественной миеломы. Онкогематология 2012; 1: 6–14. [Bessmeltsev S.S., Karyagina Ye.V., Stelmashenko L.V. i dr. Effektivnost lenalidomida pri refrakternykh/retsidiviruyushchikh formakh mnozhestvennoy miyelomy (Lenalidomide efficacy in refractory/relapsing forms of multiple myeloma. In: Oncohematology). Onkogematologiya 2012; 1: 6–14.]
  86. Siegel D.S., Martin T., Wang M. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood 2012; 120(14): 2817–25. DOI: https://doi.org/10.1182/blood-2012-05-425934
  87. Demo S.D., Kirk C.J., Aujay M.A. et al. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res. 2007; 67(13): 6383–91. DOI: https://doi.org/10.1158/0008-5472.CAN-06-4086
  88. Kuhn D.J., Chen Q., Voorhees P.M. et al. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood 2007; 110(9): 3281–90. DOI: https://doi.org/10.1182/blood-2007-01-065888
  89. Arastu-Kapur S., Anderl J.L., Kraus M. et al. Non-proteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events. Clin. Cancer Res. 2011; 17(9): 2734–43. DOI: https://doi.org/10.1158/1078-0432.CCR-10-1950
  90. Bruna J., Udina E., Ale A. et al. Neurophysiological, histological and immunohistochemical characterization of bortezomib-induced neuropathy in mice. Exp. Neurol. 2010; 223(2): 599–608. DOI: https://doi.org/10.1016/j.expneurol.2010.02.006
  91. Korde N., Zingone A., Kwok M. et al. Phase II Clinical and Correlative Study of Carfilzomib, Lenalidomide, and Dexamethasone (CRd) in Newly Diagnosed Multiple Myeloma (MM) Patients. Blood (ASH Annual Meeting Abstracts) 2012; 120: Abstract 732. DOI: https://doi.org/10.1182/blood.V120.21.732.732
  92. Barlogie B., Alexanian R., Docke K.A. High-dose chemoradiotherapy with autologous bone marrow transplantation for resistant multiple myeloma. Blood 1987; 70: 869–72. DOI: https://doi.org/10.1182/blood.V70.3.869.bloodjournal703869
  93. Attal M., Harousseau J.L., Stoppa A.M. et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myeloma. N. Engl. J. Med. 1996; 335: 91–7. DOI: https://doi.org/10.1056/NEJM199607113350204
  94. Child J.A., Morgan G.J., Davies F.E. et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N. Engl. J. Med. 2003; 348: 1875–83. DOI: https://doi.org/10.1056/NEJMoa022340
  95. Gale K. Intensive Therapy Improves Survival in Patients With Multiple Myeloma. N. Engl. J. Med. 2003; 348: 1875–83.
  96. Barlogie B., Kyle R.A., Anderson K.S. et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J. Clin. Oncol. 2006; 24: 929–36. DOI: https://doi.org/10.1200/JCO.2005.04.5807
  97. Fermand J.P., Katsahian S., Divine M. et al. High-dose therapy and autologous blood stem-cell transplantation high-dose therapy conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J. Clin. Oncol. 2005; 23: 9227–33. DOI: https://doi.org/10.1200/JCO.2005.03.0551
  98. Blade J., Rosinol L., Sureda A. et al. High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood 2005; 106: 3755–9. DOI: https://doi.org/10.1182/blood-2005-03-1301
  99. Levy V., Katsahian S., Fermand J.P. et al. A meta-analysis on data from 575 patients with multiple myeloma randomly assigned to either high-dose therapy or conventional therapy. Medicine (Baltimore) 2005; 84(4): 250–60. DOI: https://doi.org/10.1097/01.md.0000173272.71949.a1
  100. Sirohi B., Powles R., Mehta J. et al. Single-center results of 200 mg/ m2 melphalan and autograft in 451 myeloma patients: identifying patients with prolonged survival based upon albumin and B2-microglobulin at transplant. Program and abstracts of the American Society of Clinical Oncology 38th Annual Meeting. 2002, Orlando, Florida. Abstract 1072.
  101. Tribalto M., Amadori S., Cudillo L. Autologous peripheral blood stem cell transplantation as first line treatment of multiple myeloma: an Italian Multicenter Study. Haematologica 2000; 85: 52–8.
  102. Roussel M., Huynh A., Moreau P. Bortezomib and high dose melphalan as conditioning regimen before autologous stem cell transplantation for de novo multiple myeloma: final results of the IFM Phase II Study VEL/MEL. Blood 2008; 112: 160 (abstr.) DOI: https://doi.org/10.1182/blood.V112.11.160.160
  103. Van de Velde H.J., Liu X., Chen G. et al. Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma. Haematologica 2007; 92(10): 1399–406. DOI: https://doi.org/10.3324/haematol.11534
  104. Gay F., Larocca A., Wijermans P. et al. Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients. Blood 2011; 117(11): 3025–31. DOI: https://doi.org/10.1182/blood-2010-09-307645
  105. Martinez-Lopez J., Blade J., Mateos M.V. et al. Long-term prognostic significance of response in multiple myeloma after stem cell transplantation. Blood 2011; 118(3): 529–34. DOI: https://doi.org/10.1182/blood-2011-01-332320
  106. Dispenzieri A., Rajkumar S.V., Gertz M.A. et al. Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement. Mayo Clin. Proc. 2007; 82(3): 323–41. DOI: https://doi.org/10.4065/82.3.323
  107. Kumar S.K., Lacy M.Q., Dispenzieri A. et al. Early versus delayed autologous transplantation after immunomodulatory agents-based induction therapy in patients with newly diagnosed multiple myeloma. Cancer 2012; 118(6): 1585–92. DOI: https://doi.org/10.1002/cncr.26422
  108. Marjanovic S., Stamatovic D., Elez M. et al. Autologous stem cell transplantation in the treatment of patients with multiple myeloma: our experience. Bone Marrow Transplant. 2013; 48(Suppl. 2): S212 (abstr. P730).
  109. Barlogie B., Attal M., Crowley J. et al. Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the Intergroupe Francophone du Myelome, Southwest Oncology Group, and University of Arkansas for Medical Sciences. J. Clin. Oncol. 2010; 28(7): 1209–14. DOI: https://doi.org/10.1200/JCO.2009.25.6081
  110. Barlogie B., Jagannath S., Vesole D.H. et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 1997; 89: 789–93. DOI: https://doi.org/10.1182/blood.V89.3.789
  111. Barlogie B., Jagannath S., Desikan K.R. et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999; 93: 55–65. DOI: https://doi.org/10.1182/blood.V93.1.55.401k04_55_65
  112. Cavo M., Tosi P., Zamagni E. et al. A multicentric randomized clinical trial comparing single vs double autologous peripheral blood stem cell transplantation for patients with newly diagnosed multiple myeloma: results of an interim analysis. Bone Marrow Transplant. 2000; 25(Suppl. 1): S54.
  113. Lahuerta J.J., Grande C., Martinez-Lopez J. et al. Tandem transplants with different high-dose regimens improve the complete remission rates in multiple myeloma. Results of a Grupo Espanol de Sindromes Linfoproliferativos/Trasplante Autologo de Medula Osea phase II trial. Br. J. Haematol. 2003; 120: 296–303. DOI: https://doi.org/10.1046/j.1365-2141.2003.04067.x
  114. Barlogie B., Tricot G., Anaissie E. et al. Thalidomide and hematopoieticcell transplantation for multiple myeloma. N. Engl. J. Med. 2006; 354: 1021–30. DOI: https://doi.org/10.1056/NEJMoa053583
  115. Barlogie B., Anaissie E.J., Schaughnessy J.D. et al. Ninety percent sustained complete response (CR) projected 4 years after onset of CR in gene expression profiling (GEP)-defined low-risk multiple myeloma treated with Total Therapy 3 (TT3): basis for GEP-risk-adapted TT4 and TT5. Blood 2008; 12: 162 (abstr). DOI: https://doi.org/10.1182/blood.V112.11.162.162
  116. Sonneveld P., Schmidt-Wolf I.G.H., van der Holt B. et al. HOVON-65/ GMMG-HD4 randomized phase III trial comparing bortezomib, doxorubicin, dexamethasone (PAD) vs VAD followed by high-dose melphalan (HDM) and maintenance with bortezomib or thalidomide in patients with newly diagnosed multiple myeloma (MM). Blood (ASH Annual Meeting Abstracts) 2010; 116(21): Abstract 40. DOI: https://doi.org/10.1182/blood.V116.21.40.40
  117. Attal M., Harousseau J.L., Facon T. et al. InterGroupe Francophone du myeloma. Single versus double autologous stem-cell transplantation for multiple myeloma. N. Engl. J. Med. 2003; 249(26): 2495–502. DOI: https://doi.org/10.1056/NEJMoa032290
  118. Gerull S., Stem M., Ben Aissa A. et al. Allogeneic haematopoietic stem cell transplantation for multiple myeloma — the Swiss experience. Bone Marrow Transplant. 2012; 47(Suppl. 1): S326 (abstr. P899).
  119. Benakil M., Ahmed Nacer R., Talbi A. et al. Allogeneic stem cell transplantation in patients with multiple myeloma: long term follow-up in a single centre. Bone Marrow Transplant. 2012; 47(Suppl. 1): S327 (abstr. P901).
  120. Garban F., Attal M., Michallet M. et al. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in highrisk de novo multiple myeloma. Blood 2006; 107: 3477–80. DOI: https://doi.org/10.1182/blood-2005-09-3869
  121. Bruno B., Rotta M., Patriarca F. et al. A comparison of allografting with autografting for newly diagnosed myeloma. N. Engl. J. Med. 2007; 356: 1110–20. DOI: https://doi.org/10.1056/NEJMoa065464
  122. Rosinol L., Perez-Simin J.A., Sureda A. et al. A prospective PETEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma. Blood 2008; 112: 3591–3. DOI: https://doi.org/10.1182/blood-2008-02-141598
  123. Lokhorst H., Sonneveld P., van der Holt B. et al. Donor versus no donor analysis of newly diagnosed myeloma patients included in the HOVON 50/50 Study. Blood 2008; 112: 461 (abstr.). DOI: https://doi.org/10.1182/blood.V112.11.461.461
  124. Bjorkstrand B., Lacobelli S., Hegenbart A. Autologous stem cell transplantation (ASCT) versus ASCT followed by reduced-intensity conditioning (RIC) allogeneic SCT with identical sibling donor in previously untreated multiple myeloma: a prospective controlled trial by the EBMT. Bone Marrow Transplant. 2009; 43: 223 (abstr.).
  125. Kroger N., Zabelina T., Ayuk F. et al. Molecular remission after autologous-allogeneic tandem transplantation in patients with multiple myeloma. Bone Marrow Transplant. 2012; 47(Suppl. 1): S45 (abstr. O256).
  126. Kharfan-Dabaja M., Hamadani M., Reljic T. Comparative efficacy of tandem autologous-autologous versus tandem autologous-reduced intensity allogeneic haematopoietic cell transplantation in multiple myeloma: results of a systematic review and meta-analysis. Bone Marrow Transplant. 2012; 47(Suppl. 1): S44 (abstr. O254).
  127. Ludwig H., Hajek R., Tothova E. et al. Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma. Blood 2009; 113: 3435–42. DOI: https://doi.org/10.1182/blood-2008-07-169565
  128. Zonder J.A., Crowley J.J., Bolejack V. et al. A randomized Southwest Oncology Group study comparing dexamethasone (D) to lenalidomide+dexamethasone (LD) as treatment of newly diagnosed multiple myeloma: impact of cytogenetic abnormalities on efficacy of LD, and updated overall study results. J. Clin. Oncol. 2008; 26: 8521 (abstr.) DOI: https://doi.org/10.1200/jco.2008.26.15_suppl.8521
  129. Rajkumar S.V., Jacobus S., Callander N. et al. Randomized trial of lenalidomide plus high-dose dexamethasone versus lenalidomide+low-dose dexamethasone in newly diagnosed myeloma (E4A03), a trial coordinated by Eastern Cooperative Oncology Group: analysis of response, survival, and outcome. J. Clin. Oncol. 2008; 26: 8504 (abstr.). DOI: https://doi.org/10.1200/jco.2008.26.15_suppl.8504
  130. Gulbrandsen N., Waage A., Gimsing P. et al. A randomized placebo controlled study with melphalan/prednisone vs melphalan/prednisone/thalidomide: quality of life and toxicity. Haematologica 2008; 93: 93 (abstr. 0209).
  131. Palumbo A., Bringhen S., Caravita T. et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomized controlled trial. Lancet 2006; 367: 825–31. DOI: https://doi.org/10.1016/S0140-6736(06)68338-4
  132. Palumbo A., Bringhen S., Liberaty A.M. et al. Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. Blood 2008; 112: 3107–14. DOI: https://doi.org/10.1182/blood-2008-04-149427
  133. Facon T., Mary J.Y., Hulin C. et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomized trial. Lancet 2007; 370: 1209–18. DOI: https://doi.org/10.1016/S0140-6736(07)61537-2
  134. Hulin C., Facon T., Rodon P. et al. Melphalan-prednisone-thalidomide (MP-T) demonstrates a significant survival advantage in elderly patients 75 years with multiple myeloma compared with melphalan-prednisone (MP) in a randomized, double-blind, placebo-controlled trial, IFM 01/01. Blood 2007; 110: 75 (abstr.). DOI: https://doi.org/10.1182/blood.V110.11.75.75
  135. Wijermans P., Schaafsma M., van Norden Y. et al. Melphalan+prednisone vs melphalan+prednisone+thalidomide in induction therapy for multiple myeloma in elderly patients: final analysis of the Dutch cooperative group HOVON 49 study. Blood 2008; 112: 649 (abstr.). DOI: https://doi.org/10.1182/blood.V112.11.649.649
  136. San Miguel J.F., Schlag R., Khuageva N.K. et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N. Engl. J. Med. 2008; 359: 906–17. DOI: https://doi.org/10.1056/NEJMoa0801479
  137. Mateos M.V., Hernandez J.M., Hernandez M.T. et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression. Haematologica 2008; 93(4): 560–5. DOI: https://doi.org/10.3324/haematol.12106
  138. Бессмельцев С.С., Стельмашенко Л.В., Карягина Е.В. и др. Бор- тезомиб (Велкейд) в индукционной терапии множественной миеломы. Клиническая Онкогематология 2008; 1(4): 315–22. [Bessmeltsev S.S., Stelmashenko L.V., Karyagina Ye.V. i dr. Bortezomib (Velkeyd) v induktsionnoy terapii mnozhestvennoy miyelomy (Bortezomib (Velcade) in induction therapy for multiple myeloma. In: Clinical Oncohematology). Klinicheskaya Onkogematologiya 2008; 1(4): 315–22.]
  139. Бессмельцев С.С., Стельмашено Л.В., Степанова Н.В. и др. Борте- зомиб (велкейд) и мелфалан с преднизолоном в лечении множественной миеломы у пожилых больных. Онкогематология 2010; 2: 40–5.
  140. [Bessmeltsev S.S., Stelmashenko L.V., Stepanova N.V. i dr. Bortezomib (velkeyd) i melfalan s prednizolonom v lechenii mnozhestvennoy miyelomy u pozhilykh bolnykh (Bortezomib (Velcade) and melphalan with prednisolone in therapy for multiple myeloma in elderly patients. In: Oncohematology). Onkogematologiya 2010; 2: 40–5.]
  141. Бессмельцев С.С., Стельмашенко Л.В., Карягина Е.В. и др. Лечение пожилых пациентов с множественной миеломой на современном этапе. Онкогематология 2010; 4: 6–13. [Bessmeltsev S.S., Stelmashenko L.V., Karyagina Ye.V. i dr. Lecheniye pozhilykh patsiyentov s mnozhestvennoy miyelomoy na sovremennom etape (Current management of elderly patients with multiple myeloma. In: Oncohematology). Onkogematologiya 2010; 4: 6–13.]
  142. Palumbo A., Bringhen S., Rossi D. et al. A prospective, randomized, phase III study of bortezomib, melphalan, prednisone, and thalidomide (VMPT) versus bortezomib, melphalan and prednisone (VMP) in elderly newly diagnosed myeloma patients. Blood 2008; 112: 652 (abstr.) DOI: https://doi.org/10.1182/blood.V112.11.652.652
  143. Morgan G.J., Davies F.E., Owen R.G. et al. Thalidomide combinations improve response rates: results from the MRC IX Study. Blood 2007; 110: 3593 (abstr.). DOI: https://doi.org/10.1182/blood.V110.11.3593.3593
  144. Palumbo A., Falco P., Corradini P. et al. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA-Italian Multiple Myeloma Network. J. Clin. Oncol. 2007; 25: 4459–65. DOI: https://doi.org/10.1200/JCO.2007.12.3463
  145. Gay F., Bringhen S., Offidani M. et al. Efficacy and safety of 3 lenalidomidebased combinations in elderly newly diagnosed multiple myeloma patients: results from the phase 3 community based emn01 trial. 18th Congress of the European Hematology Association, June 13–16, 2013, Stockholm. Abstract B 221.
  146. Paiva B., Martinez-Lopez J. Vidriales M.B. et al. Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma. J. Clin. Oncol. 2011; 29(12): 1627–33. DOI: https://doi.org/10.1200/JCO.2010.33.1967
  147. Ladetto M., Pagliano G., Ferrero S. et al. Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. J. Clin. Oncol. 2010; 28(12): 2077–84. DOI: https://doi.org/10.1200/JCO.2009.23.7172
  148. Hoering A., Crowley J., Shaughnessy J.D. Jr. et al. Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in total therapy protocols. Blood 2009; 114(7): 1299–305. DOI: https://doi.org/10.1182/blood-2009-03-211953
  149. Myeloma Trialists’ Collaborative Group. Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients. Br. J. Haematol. 2001; 113(4): 1020–34. DOI: https://doi.org/10.1046/j.1365-2141.2001.02857.x
  150. Attal M., Harousseau J.L., Leyvraz S. et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 2006; 108: 3289–94. DOI: https://doi.org/10.1182/blood-2006-05-022962
  151. Hahn-Ast C., von Lilienfeld-Toal M., van Heteren P. et al. Improved progression-free survival and overall survival with thalidomide maintenance therapy in multiple myeloma: a meta-analyis of randomized trials in 2274 patients. Haematologica 2010; 95(2): Abstract 0942.
  152. Morgan G.J., Gregory W.M., Davies F.E. et al. The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and metaanalysis. Blood 2012; 119(1): 7–15. DOI: https://doi.org/10.1182/blood-2011-06-357038
  153. Barlogie B., Pineds-Roman M., van Rhee F. et al. Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities. Blood 2008; 112: 3115–21. DOI: https://doi.org/10.1182/blood-2008-03-145235
  154. Sonneveld P., Schmidt-Wolf I., van der Holt B. et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/GMMG-HD4 trial. J. Clin. Oncol. 2012; 30(24): 2946–55. DOI: https://doi.org/10.1200/JCO.2011.39.6820
  155. Mellqvist U.-H., Gimsing P., Hjertner O. et al. Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial. Blood 2013; 121(23): 4647–54. DOI: https://doi.org/10.1182/blood-2012-11-464503
  156. Attal M., Lauwers-Cances V., Marit G. et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N. Engl. J. Med. 2012; 366(19): 1782–91. DOI: https://doi.org/10.1056/NEJMoa1114138
  157. McCarthy P.L., Owzar K., Hofmeister C.C. et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N. Engl. J. Med. 2012; 366(19): 1770–81. DOI: https://doi.org/10.1056/NEJMoa1114083
  158. Palumbo A., Gay F., Caravita di Toritto T. et al. Melphalan/prednisone/ lenalidomide (MPR) versus high-dose melphalan and autologous transplantation (mel200) in newly diagnosed multiple myeloma patients. 18th Congress of the European Hematology Association, June 13–16, 2013, Stockholm. Abstract B 222.
  159. Cavo M., Pantani L., Petrucci M.T. et al. GIMEMA (Gruppo Italiano Malattie Ematologiche dell’Adulto) Italian Myeloma Network. Bortezomibthalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma. Blood 2012; 120(1): 9–19. DOI: https://doi.org/10.1182/blood-2012-02-408898
  160. Palumbo A., Hajek R., Delforge M. et al. Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma. N. Engl. J. Med. 2012; 366: 1759–69. DOI: https://doi.org/10.1056/NEJMoa1112704
  161. Mateos M.-V., Oriol A., Martinez-Lopez J. et al. Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial. Blood 2012; 120(13): 2581–8. DOI: https://doi.org/10.1182/blood-2012-05-427815
  162. Bergsagel P.L., Mateos M.V., Gutierrez N.C. et al. Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma. Blood 2013; 121: 884–92. DOI: https://doi.org/10.1182/blood-2012-05-432203
  163. Rajkumar S.V. Treatment of multiple myeloma. Nat. Rev. Clin. Oncol. 2011; 8(8): 479–91. DOI: https://doi.org/10.1038/nrclinonc.2011.63
  164. Nair B., van Rhee F., Shaughnessy J.D. et al. Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance. Blood 2010; 115(21): 4168–73. DOI: https://doi.org/10.1182/blood-2009-11-255620
  165. Goldschmidt H., Neben K., Bertsch U. et al. Bortezomib-based induction therapy followed by autologous stem cell transplantation and maintenance therapy with bortezomib improves outcome in myeloma patients with gain 1q21 and t(4;14): a subgroup analysis of the HOVON-65/GMMG-HD4 trial. Blood (ASH Annual Meeting Abstracts) 2010; 116(21): 305. DOI: https://doi.org/10.1182/blood.V116.21.305.305
  166. Kapoor P., Kumar S., Fonseca R. et al. Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone. Blood 2009; 114(3): 518–21. DOI: https://doi.org/10.1182/blood-2009-01-202010
  167. Jagannath S., Richardson P. G., Sonneveld P. et al. Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia 2007; 21(1): 151–7. DOI: https://doi.org/10.1038/sj.leu.2404442
  168. San-Miguel J., Harousseau J.L., Joshua D., Anderson K.C. Individualizing treatment of patients with myeloma in the era of novel agents. J. Clin. Oncol. 2008; 26(16): 2761–6. DOI: https://doi.org/10.1200/JCO.2007.15.2546
  169. Barlogie B., Anaissie E., van Rhee F. et al. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Br. J. Haematol. 2007; 138(2): 176–85. DOI: https://doi.org/10.1111/j.1365-2141.2007.06639.x
  170. Kaufman J.L., Nooka A.K., Muppidi S. et al. Survival outcomes of early autologous stem cell transplantation followed by lenalidomide, bortezomib, and dexamethasone (RVD) maintenance and patients with high-risk multiple myeloma. J. Clin. Oncol. 2012; 30: Abstract 8100. DOI: https://doi.org/10.1200/jco.2012.30.15_suppl.8100
  171. Rajkumar S.V. Doublets, triplets, or quadruplets of novel agents in newly diagnosed myeloma?. Hematology doi: 10.1182/asheducation-2012.1.354 ASH Education Book 2012; 1: 354–61. DOI: https://doi.org/10.1182/asheducation.V2012.1.354.3798330
  172. Palumbo A., Cavallo F. Have drug combinations supplanted stem cell transplantation in myeloma?. Hematology doi: 10.1182/asheducation-2012.1.354 ASH Education Book 2012; 1: 335–41. DOI: https://doi.org/10.1182/asheducation.V2012.1.335.3792205
  173. Стельмашенко Л.В., Абдулкадыров К.М., Бессмельцев С.С. и др. Роль поддерживающей терапии в посттрансплантационном периоде больных множественной миеломой. Вестн. гематол. 2012; 4: 36–7.
  174. Siegel D.S., Desikan K.R., Mehta J. et al. Age is not a prognostic variable with autotransplantants for multiple myeloma. Blood 1999; 93: 51–4. DOI: https://doi.org/10.1182/blood.V93.1.51.401a01_51_54
  175. Sirohi B., Powles R., Treleaven J. et al. The role of autologous transplantation in patients with multiple myeloma aged 65 years and over. Bone Marrow Transplant. 2000; 25: 533–9. DOI: https://doi.org/10.1038/sj.bmt.1702188
  176. Reece D.E., Bredeson C., Perez W.S. et al. Autologous stem cell transplantation in multiple myeloma patients < 60 vs >/= 60 years of age. Bone Marrow Transplant. 2003; 32: 1135–43. DOI: https://doi.org/10.1038/sj.bmt.1704288
  177. Palumbo A., Bringhen S., Petrucci M.T. et al. Intermediate-dose melphalan improves survival of myeloma patients ages 50 to 70: results of randomized controlled trial. Blood 2004; 104: 3052–3057. DOI: https://doi.org/10.1182/blood-2004-02-0408
  178. Rajkumar S.V. Thalidomide in the treatment of multiple myeloma. Expert. Rev. Anticancer Ther. 2001; 1(1): 20–8. DOI: https://doi.org/10.1586/14737140.1.1.20
  179. Weber D., Rankin K., Gavino M. et al. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J. Clin. Oncol. 2003; 21: 16–9. DOI: https://doi.org/10.1200/JCO.2003.03.139
  180. Dimopoulos M.A., Eleutherakis V. Adverse effects of thalidomide administration in patients with neoplastic disease. Am. J. Med. 2004; 117: 508–15. DOI: https://doi.org/10.1016/j.amjmed.2004.03.040
  181. Hall V.C., El-Azhary R.A., Bouwhuis S. et al. Dermatologic side effects of thalidomide in patients with multiple myeloma. J. Am. Acad. Dermatol. 2003; 48: 548–52. DOI: https://doi.org/10.1067/mjd.2003.87
  182. Palumbo A., Facon T., Sonneveld P. et al. Thalidomide for treatment of multiple myeloma: 10 years later. Blood 2008; 111: 3968–77. DOI: https://doi.org/10.1182/blood-2007-10-117457
  183. Gunzler V. Thalidomide in human immunodeficiency virus (HIV) patients: a review of safety considerations. Drug Safety 1992; 7: 116–34. DOI: https://doi.org/10.2165/00002018-199207020-00004
  184. Teo S., Morgan M., Stirling D. et al. Assessment of the in vitro and in vivo genotoxicity of thalomid (thalidomide). Terat. Carcin. Mutagen. 2000; 20: 301–11. DOI: https://doi.org/10.1002/1520-6866(2000)20:5<301::AID-TCM6>3.0.CO;2-2
  185. Sonneveld P., Dimopoulos M., San Miguel J. et al. Recommended management of cytopenia for len/dex in MM. Haematologica 2007; 92: 217 (abstr. PO-1122).
  186. Palumbo A., Rajkumar S.V., Dimopoulos M.A. et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma . Leukemia 2008; 22(2): 414–23. DOI: https://doi.org/10.1038/sj.leu.2405062
  187. Musallam K.M., Dahdaleh F.S., Shamseddine A.I., Taher A.T. Incidence and prophylaxis of venous thromboembolic events in multiple myeloma patients receiving immunomodulatory therapy. Thromb. Res. 2009; 123(5): 679–86. DOI: https://doi.org/10.1016/j.thromres.2008.09.008
  188. Cavo M., Palumbo A., Brighen S. et al. A phase III study of enoxaparin versus low-dose warfarin versus aspirin as thromboprophylaxis for patients with newly diagnosed multiple myeloma treated up-front with thalidomide-containing regimens. Blood 2008; 112: 3017 (abstr.) DOI: https://doi.org/10.1182/blood.V112.11.3017.3017
  189. Larocca A., Cavallo F., Bringhen S. et al. Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. Blood 2012; 119(4): 933–9. DOI: https://doi.org/10.1182/blood-2011-03-344333
  190. Faiman B.M., Spong J., Tariman J.D. Renal Complications in Multiple Myeloma and Related Disorders: Survivorship Care Plan of the International Myeloma Foundation Nurse Leadership Board. Clin. J. Oncol. Nurs. 2011; 15(4): 66–76. DOI: https://doi.org/10.1188/11.CJON.S1.66-76
  191. Бессмельцев С.С., Карягина Е.В., Стельмашенко Л.В. и др. Частота, характеристика и методы лечения периферической нейропатии у больных множественной миеломой, получающих бортезомиб (велкейд). Онкогема- тология 2008; 3: 52–62. [Bessmeltsev S.S., Karyagina Ye.V., Stelmashenko L.V. i dr. Chastota, kharakteristika i metody lecheniya perifericheskoy neyropatii u bolnykh mnozhestvennoy miyelomoy, poluchayushchikh bortezomib (velkeyd) (Incidence, characteristics, and therapeutic methods for management of peripheral neuropathy in patients with multiple myeloma treated with bortezomib (Velcade). In: Oncohematology). Onkogematologiya 2008; 3: 52–62.]
  192. Barohn R. Approach to peripheral neuropathy and neuronopathy. Semin. Neurol. 1998; 18: 7–18. DOI: https://doi.org/10.1055/s-2008-1040857
  193. Lopate G., Parks B., Goldstein J. et al. Polyneuropathies associated with high titre antisulphatide antibodies: characteristics of patients with and without serum monoclonal proteins. J. Neurol. Neurosurg. Psychiat. 1997; 62: 581–5. DOI: https://doi.org/10.1136/jnnp.62.6.581
  194. Ropper A.H., Gorson K.C. Neuropathies associated with paraproteinemia. N. Engl. J. Med. 1998; 338: 1601–7. DOI: https://doi.org/10.1056/NEJM199805283382207
  195. Rajkumar S.V. MGUS and Smoldering Multiple Myeloma: Update on Pathogenesis, Natural History, and Management. Hematology (The American Society of Hematology) 2005; 1: 340. DOI: https://doi.org/10.1182/asheducation-2005.1.340
  196. Richardson P.G., Delforge M., Beksac M. et al. Management of treatment-emergent peripheral neuropathy in multiple myeloma. Leukemia 2012; 26: 595–8. DOI: https://doi.org/10.1038/leu.2011.346
  197. Dispenzieri A., Jacobus S., Vesole D.H. et al. Primary therapy with single agent bortezomib as induction, maintenance and re-induction in patients with high-risk myeloma: results of the ECOG E2A02 trial. Leukemia 2010; 24: 1406–11. DOI: https://doi.org/10.1038/leu.2010.129
  198. Palumbo A., Anderson K. Multiple myeloma. Engl. J. Med. 2011; 364(11): 1046–60. DOI: https://doi.org/10.1056/NEJMra1011442

Keywords:

multiple myeloma, bortezomib, thalidomide, lenalidomide, treatment, complete remission, overall survival, neuropathy, autologous stem cell transplantation

License

Copyright (c) 2013 Clinical Oncohematology

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Downloads

Download data is not yet available.
2013-4

Downloads

Published

01.10.2013

Issue

Vol. 6 No. 4 (2013)
LYMPHOID MALIGNANCIES

How to Cite

Bessmeltsev S.S. Multiple myeloma (management of newly diagnosed patients): literature review and our on data. Part II. Clinical Oncohematology. Basic Research and Clinical Practice. 2013;6(4):379–414. doi:10.21320/2500-2139-2013-6-4-379-414.

Most read articles by the same author(s)

1 2 > >>